prediabetes and glp 1 Comparing Glucagon‐like peptide‐1 receptor agonists versus metformin in drug‐naive patients: A nationwide cohort study - Sørensen - 2024 - Journal of Diabetes WHY IS EVERYONE TALKING ABOUT

Because the needle goes into the muscle, you may feel a brief pinch or a sensation of pressure

People with cardiovascular risk factors see meaningful improvements

Who needs it

Key lipid changes with GLP-1 receptor agonists include: Triglycerides: 15-25% reduction Total cholesterol: 3-8% reduction LDL cholesterol: 3-7% reduction HDL cholesterol: 2-5% increase Non-HDL cholesterol: 5-10% reduction The SELECT cardiovascular outcomes trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease who were receiving standard background care